Back to search

Article

Antibody responses to AZD1222 vaccination in West Africa

2022-05-05

Abstract excerpt

<h4>Background</h4> There are no real world data on vaccine elicited neutralising antibody responses for the world’s most widely used vaccine, AZD1222, in African populations following scale up. Here, we measured i) baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using both flow cytometric based analysis of binding antibodies to nucleocapsid (N), cou...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5d58c7b7-e82d-5999-a680-ae27b5a75de5
DOI
10.1101/2022.05.04.22274668
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antibody responses to AZD1222 vaccination in West AfricaDOI 10.1101/2022.05.04.22274668
Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a TrialSemantic proximity
Neutralizing SARS-CoV-2 Antibody Response to 1st Dose of Astrazeneca-Oxford AZD1222 Vaccine Among Health Workers in North-Central NigeriaSemantic proximity
Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individualsSemantic proximity
Measurement of binding antibodies to SARS-CoV-2 variants elicited by natural infection and COVID-19 vaccines in a sub-Saharan African populationSemantic proximity
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings From The COV-AD StudySemantic proximity
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational studySemantic proximity
Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of ConcernSemantic proximity
Determinants of Antibody Responses to Two Doses of ChAdOx1 nCoV-19 or Bnt162b2 and a Subsequent Booster Dose of BNT162b2 or mRNA-1273: Population-Based Cohort Study (COVIDENCE UK)Semantic proximity
Comparison of kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222Semantic proximity
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccinesSemantic proximity
Kinetics of naturally induced binding and neutralizing anti-SARS-CoV-2 antibody levels and potencies among Kenyan patients with diverse grades of COVID-19 severitySemantic proximity
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Semantic proximity
Select a neighboring publication to make it the new centre.